[go: up one dir, main page]

WO2014099662A1 - Systèmes et procédés d'administration d'agents thérapeutiques - Google Patents

Systèmes et procédés d'administration d'agents thérapeutiques Download PDF

Info

Publication number
WO2014099662A1
WO2014099662A1 PCT/US2013/075005 US2013075005W WO2014099662A1 WO 2014099662 A1 WO2014099662 A1 WO 2014099662A1 US 2013075005 W US2013075005 W US 2013075005W WO 2014099662 A1 WO2014099662 A1 WO 2014099662A1
Authority
WO
WIPO (PCT)
Prior art keywords
container
region
therapeutic agent
outlet tube
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/075005
Other languages
English (en)
Inventor
Richard W. Ducharme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cook Medical Technologies LLC
Original Assignee
Cook Medical Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/725,206 external-priority patent/US9101744B2/en
Application filed by Cook Medical Technologies LLC filed Critical Cook Medical Technologies LLC
Priority to EP13818576.4A priority Critical patent/EP2934629A1/fr
Publication of WO2014099662A1 publication Critical patent/WO2014099662A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8218—Gas operated
    • A61M2205/8225—Gas operated using incorporated gas cartridges for the driving gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B7/00—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
    • B05B7/14—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas designed for spraying particulate materials
    • B05B7/1481—Spray pistols or apparatus for discharging particulate material
    • B05B7/1486—Spray pistols or apparatus for discharging particulate material for spraying particulate material in dry state

Definitions

  • the present embodiments relate generally to medical devices, and more particularly, to systems and methods for delivering therapeutic agents to a target site.
  • therapeutic agents may be introduced to achieve a biological effect.
  • the biological effect may include an array of targeted results, such as inducing hemostasis, sealing perforations, reducing restenosis likelihood, or treating cancerous tumors or other diseases.
  • IV intravenous
  • Many of such therapeutic agents are injected using an intravenous (IV) technique and via oral medicine. While such techniques permit the general introduction of medicine, in many instances it may be desirable to provide localized or targeted delivery of therapeutic agents, which may allow for the guided and precise delivery of agents to selected target sites. For example, localized delivery of therapeutic agents to a tumor may reduce the exposure of the therapeutic agents to normal, healthy tissues, which may reduce potentially harmful side effects.
  • Localized delivery of therapeutic agents has been performed using catheters and similar introducer devices.
  • a catheter may be advanced towards a target site within the patient, then the therapeutic agent may be injected through a lumen of the catheter to the target site.
  • a syringe or similar device may be used to inject the therapeutic agent into the lumen of the catheter.
  • such a delivery technique may result in a relatively weak stream of the injected therapeutic agent.
  • a therapeutic powder may not be easily delivered through a catheter to a target site in a localized manner that may also reduce potentially harmful side effects.
  • the present embodiments provide systems and methods suitable for delivering a therapeutic agent to a target site.
  • the systems generally comprise a container having first and second regions and a reservoir containing the therapeutic agent.
  • a pressure source having pressurized fluid is in selective fluid communication with at least a portion of the reservoir.
  • An outlet tube is in fluid communication with the reservoir of the container. At least one slot is formed in a lateral surface of the outlet tube at a position between first and second ends of the outlet tube.
  • the first end of the outlet tube may be disposed closer to a target site and the second end of the outlet tube may be disposed proximal to the first end, and the at least one slot may be positioned closer to the first end than the second end of the outlet tube.
  • the at least one slot extends between about 45 and about 270 degrees around a perimeter of the outer tube.
  • fluid from the pressure source is directed through a first region of the container in a direction towards a second region of the container.
  • the fluid then is at least partially redirected to urge the therapeutic agent in a direction from the second region of the container towards the first region of the container and subsequently towards the target site.
  • an inlet tube may be disposed within the container, such that the fluid from the pressure source flows through the inlet tube and into the reservoir of the container.
  • the fluid from the inlet tube may be redirected to then flow in a direction from the second region of the container towards the first region of the container.
  • the outlet tube may be disposed at least partially within the container, wherein fluid exiting the second end of the inlet tube urges the therapeutic agent into the second end of the outlet tube.
  • FIG. 1 is a perspective view of a system in accordance with a first embodiment.
  • FIG. 2 is a schematic view of the system of FIG. 1 with a portion of a housing removed.
  • FIG. 3 is a side-sectional view of the container of the system of FIGS. 1-2.
  • FIG. 4 is a perspective view of a system in accordance with an alternative embodiment.
  • FIG. 5 is a perspective view of a system in accordance with a further alternative embodiment.
  • FIG. 6 is a perspective view of a system in accordance with yet a further alternative embodiment.
  • FIG. 7 is a schematic view of the system of FIG. 6 with a portion of a housing removed.
  • FIG. 8 is a perspective view of the container of the system of FIGS. 6-7.
  • FIG. 9 is a schematic view of a system in accordance with yet a further alternative embodiment with a portion of a housing removed.
  • FIG. 10 is a perspective view of the container of the system of FIG. 9.
  • FIG. 11 is a side-sectional view of a portion of a system in accordance with an alternative embodiment.
  • FIG. 12 is a side-sectional view of an alternative actuator arrangement.
  • FIG. 13 is a perspective view of a system in accordance with an alternative outlet tube relative to the embodiment of FIG. 1.
  • FIG. 14 is a side view illustrating a section of the alternative outlet tube of FIG. 13.
  • proximal refers to a direction that is generally towards a physician during a medical procedure
  • distal refers to a direction that is generally towards a target site within a patient's anatomy during a medical procedure.
  • the system 20 comprises a container 30 that is configured to hold a therapeutic agent 38, and further comprises at least one pressure source 68 that is configured to be placed in selective fluid communication with at least a portion of the container 30, to deliver the therapeutic agent 38 through a catheter 90 to a target site within the patient, as explained more fully below.
  • the system 20 further comprises a housing 22, which is suitable for securely holding, engaging and/or covering the container 30, pressure source 68, catheter 90, and other components described below.
  • the housing 22 comprises an upright section 24 that may be grasped by a user and a section 25 for engaging the container 30.
  • Actuators 26 and 28 may be engaged by a user and selectively operated to perform the functions described below.
  • the container 30 may comprise any suitable size and shape for holding the therapeutic agent 38.
  • the container 30 comprises a generally tube-shaped configuration having a first region 31, a second region 32, and a reservoir 33 defined by an interior of the container 30.
  • a platform 35 may be positioned within the container 30 above a curved end region 34, as best seen in FIG. 3.
  • the platform 35 preferably forms a substantially fluid tight seal with an inner surface of the container 30, thereby preventing the therapeutic agent 38 that is disposed in the reservoir 33 from reaching an inner portion of the curved end region 34, as shown in FIG. 3.
  • the platform 35 comprises an opening 36 though which fluid from the pressure source 68 is directed via a u-shaped tube 37 disposed within the curved end region 34, as shown in FIG. 3 and explained in further detail below.
  • the container 30 may further comprise an inlet tube 40, an outlet tube 50, and a cap 60, wherein the cap 60 is configured to be secured to the first region 31 of the container 30, as depicted in FIG. 3.
  • the inlet tube 40 has first and second ends 41 and 42 with a lumen 43 extending therebetween, while the outlet tube 50 has first and second ends 51 and 52 with a lumen 53 extending therebetween.
  • the first end 41 of the inlet tube 40 is placed in fluid communication with an inlet port 61 formed in the cap 60, while the first end 51 of the outlet tube 50 is placed in fluid communication with an outlet port 62 formed in the cap 60, as shown in FIG. 3.
  • the second end 42 of the inlet tube 40 extends towards the platform 35, and may be coupled to an adapter 44, which may be integral with the platform 35 or secured thereto.
  • the adapter 44 places the second end 42 of the inlet tube 40 in fluid communication with a first end 45 of the u-shaped tube 37, which is disposed within the curved end region 34, as shown in FIG. 3.
  • a second end 46 of the u-shaped tube 37 is in fluid communication with the opening 36 in the platform 35.
  • fluid passed through the inlet port 61 of the cap 60 is directed through the inlet tube 40, through the u-shaped tube 37, and into the reservoir 33 via the opening 36.
  • the u-shaped tube 37 effectively changes the direction of the fluid flow by approximately 180 degrees, such that the fluid originally flows in a direction from the first region 31 of the container 30 towards the second region 32, and then from the second region 32 back towards the first region 31.
  • the first region 31 of the container 30 is disposed vertically above the second region 32 of the container 30 during use, however, it is possible to have different placements of the first and second regions 31 and 32 relative to one another, such that they are disposed at least partially horizontally adjacent to one another.
  • the second end 52 of the outlet tube 50 may terminate a predetermined distance above the platform 35, as shown in FIGS. 1-3. While the second end 52 is shown relatively close to the platform 35 in this embodiment, any suitable predetermined distance may be provided. For example, the outlet tube 50 may be shorter in length, e.g., about half of the length shown in FIGS. 1-3, and therefore, the second end 52 may be spaced apart further from the platform 35. In a presently preferred embodiment, the second end 52 of the outlet tube 50 is radially aligned with the opening 36 in the platform 35, as depicted in FIGS. 1-3.
  • the fluid and the therapeutic agent 38 within the reservoir 33 may be directed through the outlet tube 50, through the outlet port 62, and towards a target site.
  • the outlet tube 50 may be omitted and the therapeutic agent 38 may flow directly from the reservoir 33 into the outlet port 62.
  • Other variations on the container 30 and outlet port 62 may be found in U.S. Pat. App. Serial No. 12/633,027, filed December 8, 2009, which is hereby incorporated by reference in its entirety.
  • the cap 60 may comprise any suitable configuration for sealingly engaging the first region 31 of the container 30.
  • an O-ring 65 is held in place around a circumference of the cap 60 to hold the therapeutic agent 38 within the reservoir 33.
  • the cap 60 may comprise one or more flanges 63 that permit a secure, removable engagement with a complementary internal region of the section 25 of the housing 22. For example, by rotating the container 30, the flange 63 of the cap 60 may lock in place within the section 25.
  • the inlet and outlet tubes 40 and 50 may be held in place within the container 30 by one or more support members.
  • a first support member 48 is secured around the inlet and outlet tubes 40 and 50 near their respective first ends 41 and 51, as shown in FIG. 3.
  • the first support member 48 may be permanently secured around the inlet and outlet tubes 40 and 50, and may maintain a desired spacing between the tubes.
  • a second support member 49 may be secured around the inlet and outlet tubes 40 and 50 near their respective second ends 42 and 52, as shown in FIGS. 1-3.
  • greater or fewer support members may be provided to hold the inlet and outlet tubes 40 and 50 in a desired orientation within the container 30.
  • the second support member 49 may be omitted and just the first support member 48 may be provided, or greater than two support members may be used.
  • the inlet and outlet tubes 40 and 50 may be securely coupled to the first support member 48, the second support member 49, the platform 35 and the u- shaped tube 37.
  • the platform 35 may be advanced towards the second region 32 of the empty container 30 until the platform rests on a step 47 above the curved end region 35 of the container 30, as shown in FIG. 3.
  • a desired quantity of the therapeutic agent 38 may be loaded through slits 57 formed adjacent to, or within, the first support member 48, as depicted in FIG. 3.
  • the container 30 also may comprise measurement indicia 39, which allow a user to determine a quantity of the therapeutic agent 38 that is loaded within the reservoir 33 as measured, for example, from the top of the platform 35.
  • the cap 60 may be securely coupled to the first region 31 of the container 30, and the container 30 then is securely coupled to the section 25 of the handle 22 as described above.
  • the pressure source 68 may comprise one or more components capable of producing or furnishing a fluid having a desired pressure.
  • the pressure source 68 may comprise a pressurized fluid, such as a liquid or gas.
  • the pressure source 68 may comprise a pressurized fluid cartridge of a selected gas or liquid, such as carbon dioxide, nitrogen, or any other suitable gas or liquid that may be compatible with the human body.
  • the pressurized fluid cartridge may contain the gas or liquid at a relatively high, first predetermined pressure, for example, around 1,800 psi inside of the cartridge.
  • the pressure source 68 optionally may comprise one or more commercially available components.
  • the pressure source 68 therefore may comprise original or retrofitted components capable of providing a fluid or gas at an original pressure.
  • the fluid may flow from the pressure source 68 through a pressure regulator, such as regulator valve 70 having a pressure outlet 72, as depicted in FIG. 2, which may reduce the pressure to a lower, second predetermined pressure.
  • a pressure regulator such as regulator valve 70 having a pressure outlet 72, as depicted in FIG. 2, which may reduce the pressure to a lower, second predetermined pressure.
  • the second predetermined pressure may be in the range of about 30 to about 80 psi, although any suitable pressure may be provided for the purposes described below.
  • the actuator 26 may be actuated to release the fluid from the pressure source 68.
  • a user may rotate the actuator 26, which translates into linear motion via a threaded engagement 29 between the actuator 26 and the housing 22, as shown in FIG. 2.
  • the regulator valve 70 may pierce through a seal of the pressure cartridge to release the high pressure fluid. After the regulator valve 70 reduces the pressure, the fluid may flow from the pressure outlet 72 to an actuation valve 80 via tubing 75.
  • the actuation valve 80 comprises an inlet port 81 and an outlet port 82.
  • the actuator 28, which may be in the form of a depressible button, may selectively engage the actuation valve 80 to selectively permit fluid to pass from the inlet port 81 to the outlet port 82.
  • the actuation valve 80 may comprise a piston having a bore formed therein that permits fluid flow towards the outlet port 82 when the actuator 28 engages the actuation valve 80. Fluid that flows through the outlet port 82 is directed into the inlet port 61 of the cap 60 via tubing 85, and subsequently is directed into the container 30, as explained above. It will be appreciated that any suitable coupling mechanisms may be employed to secure the various pieces of tubing to the various valves and ports.
  • the system 20 further may comprise one or more tube members for delivering the therapeutic agent 38 to a target site.
  • the tube member may comprise a catheter 90 having a proximal end that may be placed in fluid communication with the outlet port 62.
  • the catheter 90 further comprises a distal end that may facilitate delivery of the therapeutic agent 38 to a target site.
  • the catheter 90 may comprise a flexible, tubular member that may be formed from one or more semi-rigid polymers.
  • the catheter may be manufactured from polyurethane, polyethylene, tetrafluoroethylene, polytetrafluoroethylene, fluorinated ethylene propylene, nylon, PEBAX or the like. Further details of a suitable tube member are described in U.S. Patent Serial No.
  • a needle suitable for penetrating tissue may be coupled to the distal end of the catheter 90 to form a sharp, distal region configured to pierce through a portion of a patient's tissue, or through a lumen wall to perform a translumenal procedure.
  • the distal end of the catheter 90 may be positioned in relatively close proximity to the target site.
  • the catheter 90 may be advanced to the target site using an open technique, a laparoscopic technique, an intraluminal technique, using a gastroenterology technique through the mouth, colon, or using any other suitable technique.
  • the catheter 90 may comprise one or more markers configured to be visualized under fluoroscopy or other imaging techniques to facilitate location of the distal end of the catheter 90. If desired, the catheter 90 may be advanced through a working lumen of an endoscope.
  • the pressure source 68 may be actuated by engaging the actuator 26.
  • the pressurized fluid may flow from the pressure source 68 through a regulator valve 70 and be brought to a desired pressure and rate.
  • the fluid then flows through the tubing 75, and when the actuator 28 is selectively depressed, the fluid flows through the valve 80 and through the tubing 85 towards the container 30.
  • the fluid is then directed through the inlet port 62, through the inlet tube 40 within the container 30, and through the u-shaped tube 37.
  • the u-shaped tube effectively changes the direction of the fluid flow.
  • Regulated fluid then flows through the opening 36 in the platform 35 and urges the therapeutic agent 38 through the outlet tube 50.
  • the fluid and the therapeutic agent 38 then exit through the first end 51 of the outlet tube 50, through the outlet port 62 of the cap 60, and through the catheter 90, thereby delivering the therapeutic agent 38 to the target site at a desired pressure.
  • a control mechanism may be coupled to the system 20 to variably permit fluid flow into and/or out of the container 30 at a desired time interval, for example, a predetermined quantity of fluid per second.
  • pressurized fluid may periodically flow into or out of the container 30 periodically to deliver the therapeutic agent 38 to a target site at a predetermined interval or otherwise periodic basis.
  • the system 20 may be used to deliver the therapeutic agent 38 in a wide range of procedures and the therapeutic agent 38 may be chosen to perform a desired function upon ejection from the distal end of the catheter 90. Solely by way of example, and without limitation, the provision of the therapeutic agent 38 may be used for providing hemostasis, closing perforations, performing lithotripsy, treating tumors and cancers, treat renal dialysis fistulae stenosis, vascular graft stenosis, and the like.
  • the therapeutic agent 38 can be delivered during procedures such as coronary artery angioplasty, renal artery angioplasty and carotid artery surgery, or may be used generally for treating various other cardiovascular, respiratory, gastroenterology or other conditions.
  • the above-mentioned systems also may be used in transvaginal, umbilical, nasal, and bronchial/lung related applications.
  • thrombin, epinephrine, or a sclerosant may be provided to reduce localized bleeding.
  • a fibrin sealant may be delivered to a localized lesion.
  • the relatively high pressure of the fluid and therapeutic agent by itself, may act as a mechanical tamponade by providing a compressive force, thereby reducing the time needed to achieve hemostasis.
  • the therapeutic agent 38 may be selected to perform one or more desired biological functions, for example, promoting the ingrowth of tissue from the interior wall of a body vessel, or alternatively, to mitigate or prevent undesired conditions in the vessel wall, such as restenosis. Many other types of therapeutic agents 38 may be used in conjunction with the system 20. [0050]
  • the therapeutic agent 38 may be delivered in any suitable form.
  • the therapeutic agent 38 may comprise a powder, liquid, gel, aerosol, or other substance.
  • the pressure source 68 may facilitate delivery of the therapeutic agent 38 in any one of these forms.
  • the therapeutic agent 38 employed also may comprise an antithrombogenic bioactive agent, e.g., any bioactive agent that inhibits or prevents thrombus formation within a body vessel.
  • antithrombotic bioactive agents include anticoagulants, antiplatelets, and fibrinolytics.
  • Anticoagulants are bioactive materials which act on any of the factors, cofactors, activated factors, or activated cofactors in the biochemical cascade and inhibit the synthesis of fibrin.
  • Antiplatelet bioactive agents inhibit the adhesion, activation, and aggregation of platelets, which are key components of thrombi and play an important role in thrombosis.
  • Fibrinolytic bioactive agents enhance the fibrinolytic cascade or otherwise aid in dissolution of a thrombus.
  • antithrombotics include but are not limited to anticoagulants such as thrombin, Factor Xa, Factor Vila and tissue factor inhibitors; antiplatelets such as glycoprotein Ilb/IIIa, thromboxane A2, ADP-induced glycoprotein Ilb/IIIa, and phosphodiesterase inhibitors; and fibrinolytics such as plasminogen activators, thrombin activatable fibrinolysis inhibitor (TAFI) inhibitors, and other enzymes which cleave fibrin.
  • anticoagulants such as thrombin, Factor Xa, Factor Vila and tissue factor inhibitors
  • antiplatelets such as glycoprotein Ilb/IIIa, thromboxane A2, ADP-induced glycoprotein Ilb/IIIa, and phosphodiesterase inhibitors
  • fibrinolytics such as plasminogen activators, thrombin activatable fibrinolysis inhibitor (TAFI) inhibitors, and other enzymes which cleave fibrin.
  • TAFI thrombin activatable fibr
  • the therapeutic agent 38 may include thrombolytic agents used to dissolve blood clots that may adversely affect blood flow in body vessels.
  • a thrombolytic agent is any therapeutic agent that either digests fibrin fibers directly or activates the natural mechanisms for doing so.
  • Examples of commercial thrombolytics include, but are not limited to, Abbokinase (urokinase), Abbokinase Open-Cath (urokinase), Activase (alteplase, recombinant), Eminase (anitstreplase), Retavase (reteplase, recombinant), and Streptase (streptokinase).
  • Other commonly used names are anisoylated plasminogen-streptokinase activator complex; APSAC; tissue-type plasminogen activator (recombinant); t-PA; rt-PA.
  • the therapeutic agent 38 comprises a hemostasis powder manufactured by TraumaCure, Inc. of Bethesda, MD.
  • TraumaCure, Inc. of Bethesda, MD.
  • the system 20 permits localized delivery of a desired quantity of the therapeutic agent 38 at a desired, regulated pressure. Since the distal end of the catheter 90 may be placed in relatively close proximity to a target site, the system 20 provides significant advantages over therapeutic agents delivered orally or through an IV system and may reduce accumulation of the therapeutic agent 38 in healthy tissues, thereby reducing side effects.
  • the delivery of the therapeutic agent 38 to the target site is performed in a relatively fast manner due to the relatively high pressure of the fluid, thereby providing a prompt delivery to the target site compared to previous devices.
  • the system 20 advantageously may be used to both perforate tissue at or near a target site, then deliver the therapeutic agent 38 at a desired pressure in the manner described above.
  • the needle may comprise an endoscopic ultrasound (EUS) needle.
  • EUS endoscopic ultrasound
  • a sharpened tip of the needle may be capable of puncturing through an organ or a gastrointestinal wall or tissue, so that the therapeutic agent 38 may be delivered at a predetermined pressure in various bodily locations that may be otherwise difficult to access.
  • One or more delivery vehicles such as an endoscope or sheath, may be employed to deliver the catheter 90 to a target site, particularly if the distal end of the catheter 90 comprises the optional needle.
  • the alternative system 20' comprises an inlet tube 40' having a J-shaped curvature 93 that causes a second end 42' of the inlet tube 40' to direct fluid flow in a substantially opposing direction relative to the first end 41 of the inlet tube 40'.
  • fluid from the pressure source 68 flows through the first end 41 of the inlet tube 40', through the J-shaped curvature 93 and exits the second end 42', thereby directing the therapeutic agent 38 (not shown in FIG. 4) into the outlet tube 50 for delivery to a target site via the catheter 90, as generally explained above.
  • the platform 35 may be omitted and the therapeutic agent 38 may settle on a lower region of the reservoir 33.
  • Measurement indicia 39' may measure a quantity of the therapeutic agent 38 from the lower region of the reservoir 33.
  • a filter may cover the second end 52 of the outlet tube 50.
  • the filter may be sized to ensure that only relatively small particles of the therapeutic agent 38 enter into the outlet tube 50, thereby reducing the risk of clogging. If relatively large particles become present in the reservoir 33, the fluid from the pressure source 68 entering into the container may break up the larger particles until they are small enough to pass through the filter and into the outlet tube 50.
  • the alternative system 20" comprises an inlet tube 40" having a curvature 94 that directs fluid into a flow assembly 95.
  • the flow assembly 95 has an inlet 96 comprising at least one bore configured for fluid communication with the second end 42" of the inlet tube 40".
  • the flow assembly 95 further comprises an outlet 98 that is coupled to, and in fluid communication with, the second end 52 of the outlet tube 50.
  • At least one opening 97 is formed in a lateral surface of the flow assembly 95 between the inlet 96 and the outlet 98, wherein the openings 97 are sized to permit suctioning of the therapeutic agent 38 therethrough.
  • the openings 97 may comprise slits, as generally depicted, or alternatively circular bores or other shapes.
  • fluid from the pressure source 68 flows through the first end 41 of the inlet tube 40", through the curvature 94 and the second end 42", and into the flow assembly 95 via the inlet 96.
  • the fluid thereby directs the therapeutic agent 38 within the reservoir 33 into the outlet tube 50, via the openings 97, for delivery to a target site via the catheter 90.
  • a localized low pressure system will be provided in the vicinity of the openings 97 in accordance with Bernoulli's principle of fluid dynamics.
  • the low pressure system formed by the presence of the pressurized fluid passing through the flow assembly 95 will form a strong suction force when it passes by the openings 97.
  • the therapeutic agent 38 may be suctioned out of the reservoir 33, through the openings 97 and through the outlet 98 and outlet tube 50.
  • the slits or other openings may be sized to ensure that only relatively small particles of the therapeutic agent 38 enter into the outlet tube 50, thereby reducing the risk of clogging.
  • the system 120 comprises a housing 122, which is suitable for securely holding, engaging and/or covering the components described below.
  • a user may hold the system 120 during use by grasping an upright support 125 and/or an outer surface of a container 130.
  • Actuators 126 and 128, which are similar to actuators 26 and 28 above, may be engaged by a user and actuated to perform the functions described below.
  • the container 130 may comprise any suitable size and shape for holding the therapeutic agent 38 described above (not shown in FIGS. 6-8 for illustrative purposes).
  • the container 130 has a first region 131 and a second region 132.
  • An upper cap 160 may securely engage the first region 131, while a lower cap 165 may securely engage the second region 132, thereby holding the therapeutic agent 38 within a reservoir 133.
  • Measurement indicia 139 are provided to determine a quantity of the therapeutic agent 38 within the reservoir 133.
  • an outlet tube 150 having first and second ends 151 and 152 is positioned within the container 130.
  • the second end 152 of the tube 150 terminates a predetermined distance above an upper surface 168 of the lower cap 165, as shown in FIGS. 6-8. Further, the second end 152 of the outlet tube 150 may be aligned with an opening 166 in the upper surface 168 of the lower cap 165, as depicted in FIGS. 6 and 8.
  • the system 120 further comprises at least one linkage 177 having first and second ends 178 and 179.
  • the first end 178 of the linkage 177 is coupled to the actuator 128, while the second end 179 of the linkage 177 is coupled to the valve 80. Accordingly, when the actuator 128 is depressed, the valve 80 may be selectively actuated.
  • the container 130 may comprise a groove 137, as best seen in FIG. 8, for accommodating the linkage 177.
  • the upper and lower caps 160 and 165 also may comprise corresponding grooves 162 and 167, respectively, for accommodating the linkage 177. It will be apparent that any number of linkages may be used, and their positioning within the housing 122 may be varied, as needed, to impart a desired motion from the actuator 128 to selectively actuate the valve 80.
  • an orientation device 193 may be used for indicating a vertical orientation of the container 130.
  • the orientation device 193 may be formed integrally with the housing 122, or coupled to an exterior surface of the housing 122.
  • the orientation device 193 may comprise a captive liquid, ball, arrow or other member, or an electronic display, which provides an indication of the vertical orientation of the container 130. Therefore, when the system 120 is held in a user's hand, the user may determine whether the container 130 is oriented vertically, which may enhance flow of the therapeutic agent 38 and other functionality.
  • the orientation device 193 shown in FIGS. 6-7 also may be used in the embodiments of FIGS. 1-5 and 8-9.
  • Operation of the system 120 is similar to the operation of the system 20 described above.
  • the pressure source 68 may be actuated by engaging the actuator 126.
  • the pressurized fluid may flow through a regulator valve 70 and be brought to a desired pressure and rate.
  • the fluid then flows through the tubing 75, and when the actuator 28 is selectively actuated, the fluid flows through the valve 80 and through the tubing 85 towards the container 130.
  • Regulated fluid then flows through the opening 166 within the lower cap 165, into the reservoir 133, and urges the therapeutic agent 38 through the outlet tube 150 in a direction from the second end 152 towards the first end 151.
  • the fluid and the therapeutic agent 38 then exit through the first end 151 of the outlet tube 150, through the opening 161 of the upper cap 160, and through the catheter 90, which is in fluid communication with the opening 161. Accordingly, the therapeutic agent 38 is delivered to the target site at a desired interval and pressure.
  • the system 220 comprises a housing 222, which is suitable for securely holding, engaging and/or covering the components described below.
  • a user may hold the system 220 during use by grasping a generally upright support 225.
  • Actuators 226 and 228, which are similar to actuators 26 and 28 above, may be engaged by a user and actuated to perform the functions described below.
  • an alternative container 230 comprises a reservoir 233 for holding the therapeutic agent 38 described above (not shown in FIGS. 9-10 for illustrative purposes).
  • the container 230 has a first region 231 and a second region 232.
  • Measurement indicia 239 are provided to determine a quantity of the therapeutic agent 38 within the reservoir 233.
  • the second region 232 of the container 230 is securely coupled to a lower cap 234.
  • the lower cap 234 comprises an inlet port 243, which is in fluid communication with an opening 236 formed in an upper surface 235 of the lower cap 234.
  • a flexible u-shaped tube 237 may be coupled between the inlet port 243 and the opening 236 to provide fluid communication therebetween, as depicted in FIG. 9.
  • the system 220 further comprises at least one linkage 277 having first and second ends 278 and 279.
  • the first end 278 of the linkage 277 is coupled to the actuator 228, while the second end 279 of the linkage 277 may be pivotable about an inner element of the housing 222.
  • the second end 279 may comprise a bore, as shown in FIG. 9, which may be secured around a prong (not shown) extending within the housing 222, thereby allowing the second end 279 to pivot around the prong.
  • a central region of the linkage 277 may engage the valve 80 to selectively actuate the valve and permit flow therethrough.
  • any number of linkages may be used, and their positioning within the housing 222 may be varied, as needed, to impart a desired motion from the actuator 228 to selectively actuate the valve 80.
  • Operation of the system 220 is similar to the operation of the system 20 described above.
  • the pressure source 68 may be actuated by engaging the actuator 226.
  • the pressurized fluid may flow through a regulator valve 70 and be brought to a desired pressure and rate.
  • the fluid then flows through the tubing 75, and when the actuator 228 is selectively actuated, the fluid flows through the valve 80 and through the tubing 85.
  • Fluid then flows through the inlet port 243, through the u-shaped tube positioned within the lower cap 234, through the opening 236 and into the reservoir 233. Fluid entering the reservoir 233 then urges the therapeutic agent 38 through an outlet port 261 at the first region 231 of the container 230.
  • the first region 231 may comprise a curve or taper 249 to direct the fluid and the therapeutic agent 38 through the opening 261. Subsequently, the fluid and the therapeutic agent 38 flow through the catheter 90, which is in fluid communication with the opening 261, thereby delivering the therapeutic agent 38 to the target site at a desired pressure.
  • outlet tubes 50 and 150 of FIGS. 1-5 and 6-8 may be omitted. Therefore, fluid entering into the reservoirs 33 and 133 may urge the therapeutic agent 38 in a direction through outlet port in the caps 60 and 160. A taper or curve may be provided to guide the therapeutic agent 38 out of the containers 30 and 130.
  • an outlet tube 350 has a first end 351 that is coupled to an outlet port 362 formed in a distal tip of the housing 322.
  • the outlet port 362 has proximal and distal regions 363 and 364, whereby the proximal region 363 is configured to securely engage the first end 351 of the outlet tube 350, and the distal region 364 is configured to be coupled to the catheter 90 of FIGS. 1-2.
  • a luer-type connection may be provided.
  • a physician may easily exchange the catheter 90 during a procedure, for example, if the catheter 90 becomes occluded.
  • FIG. 11 depicts an alternative connection of a container 330 to the housing 322.
  • the container 330 is similar to the container 30 described above, but in the embodiment of FIG. 11, a cap of the container 330 comprises a flanged region 363 having an O-ring 365 disposed therein, wherein the flanged region 363 is configured to be secured between upper and lower internal stops 388 and 389 of the housing 322.
  • the flanged region 363 of the cap may be held in place without the ability to be removed, thereby permanently securing the container 330 to the handle 322 and eliminating the opportunity for the container 330 to be reusable.
  • other features of the cap of FIG. 11 that are not shown may be provided in a manner similar to the cap 60 of FIG. 3, such as the inlet port 61.
  • an alternative actuator 426 is provided, which is generally similar to the actuator 26 of FIGS. 1-2, with a main exception that there is provided a lower handle portion 427 and a generally upright portion 428 that extends vertically within the housing 422 and upwards beyond a portion of a regulator valve 70.
  • An upper region of the generally upright portion 428 comprises threading 429, which is configured to engage threading on an outer surface of the regulator valve 70.
  • a user may rotate the lower handle portion 427 of the actuator 426, which translates into linear motion relative to the regulator valve 470 via the threaded engagement 429.
  • the regulator valve 470 may pierce through a seal of the pressure cartridge to release the high pressure fluid.
  • the fluid may flow from the pressure outlet 72 to an actuation valve 80 via tubing 75, in the manner explained in FIG. 2 above.
  • a safety ledge or interference may be provided on the housing 422 to prevent the actuator 426 from becoming disengaged, which could otherwise allow the pressure cartridge to be ejected from the device.
  • a system 20' for delivering a therapeutic agent is similar to system 20 of the embodiment of FIGS. 1-3, with a main exception that an alternative outlet tube 50' comprises at least one slot 55 formed in a lateral surface of the outlet tube 50'.
  • the slot 55 is formed in the lateral surface at a location between the first and second ends 51 and 52 of the outlet tube 50'.
  • the slot 55 provides an area of communication between the lumen 53 (shown in FIG. 3 above) of the outlet tube and the reservoir 33 defined by an interior of the container 30'.
  • the slot 55 extends between about 45 and about 270 degrees around a perimeter of the outlet tube 50', as depicted in FIGS. 13-14.
  • the slot 55 may be positioned at a location closer to the first end 51 than the second end 52, as depicted in FIG. 13.
  • FIGS. 13-14 it is possible that multiple slots may be formed in a lateral surface of the outlet tube 50', at locations that are axially spaced apart and/or circumferentially offset from the slot 55 depicted in FIG. 13.
  • the location of the slot 55 that is depicted in FIG. 13 is not intended to be limiting.
  • the inventor has surprisingly discovered that the provision of the at least one slot 55 may reduce the incidence of the device "burping" the therapeutic agent 38 after the actuator 28 is disengaged by the operator. Furthermore, the provision of the slot 55 may reduce the amount of the therapeutic agent 38 that is left in the catheter 90 that can cause the catheter 90 to clog when it is in contact with blood.
  • the fluid from the pressure source 68 is allowed to enter the reservoir 33 holding the therapeutic agent 38 to enable delivery of the therapeutic agent 38 to a target site, as described above. It has been discovered that some pressure builds up in the reservoir 33 when the actuator 28 is engaged. When the operator disengages the actuator 28, there is still some pressure in the reservoir 33. In the absence of the slot 55, the therapeutic agent 38 can fall to the bottom of the reservoir 33 due to gravity, and then the pressurized fluid from regions above within the reservoir 33 may push a "burp" of the therapeutic agent 38 from the device as the fluid pressure is reduced. It has been found that this can leave some of the therapeutic agent 38 within the catheter 90, which can cause clogging. Moreover, an operator may unexpectedly find that some of the therapeutic agent 38 is still being deployed from the catheter 90, even after they have disengaged actuation of the actuator 28.
  • the at least one slot 55 By placing the at least one slot 55 in a lateral surface of the outlet tube 50', the aforementioned potential drawbacks can be avoided.
  • the slot 55 is positioned closer to the first end 51 than the second end 52, i.e., higher up when used in a generally vertical orientation as depicted in FIG. 13, then instead of forcing the therapeutic agent 38 that has settled down in the reservoir 33 out of the catheter 90 when some pressure remains in the reservoir 33, the pressurized fluid itself can exit the reservoir 33 via the slot 55 near the top of the outlet tube 50'. This action has been found to effectively purge the catheter 90 with substantially only the pressurized fluid, thereby reducing the instance of "burping" with the therapeutic agent 38 and catheter clogging by the therapeutic agent 38.
  • At least one slot 55 has been shown as being disposed in a lateral surface of the outlet tube 50' in a modified version of the embodiment of FIGS. 1-3, at least one slot may be provided in any of the outlet tubes of the alternative embodiments described herein, i.e., besides the embodiment of FIGS. 1-3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Les modes de réalisation de la présente invention concernent des systèmes et des procédés appropriés pour administrer un agent thérapeutique à un site cible. Les systèmes comprennent de manière générale un récipient ayant des première et seconde régions et un réservoir contenant l'agent thérapeutique. Une source de pression ayant un fluide mis sous pression est en communication fluidique sélective avec au moins une partie du réservoir. Un tube de sortie est en communication fluidique avec le réservoir du récipient. Au moins une fente est formée dans une surface latérale du tube de sortie à une position entre des première et seconde extrémités du tube de sortie.
PCT/US2013/075005 2012-12-21 2013-12-13 Systèmes et procédés d'administration d'agents thérapeutiques Ceased WO2014099662A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13818576.4A EP2934629A1 (fr) 2012-12-21 2013-12-13 Systèmes et procédés d'administration d'agents thérapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/725,206 2012-12-21
US13/725,206 US9101744B2 (en) 2009-05-29 2012-12-21 Systems and methods for delivering therapeutic agents

Publications (1)

Publication Number Publication Date
WO2014099662A1 true WO2014099662A1 (fr) 2014-06-26

Family

ID=49920633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/075005 Ceased WO2014099662A1 (fr) 2012-12-21 2013-12-13 Systèmes et procédés d'administration d'agents thérapeutiques

Country Status (2)

Country Link
EP (1) EP2934629A1 (fr)
WO (1) WO2014099662A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164723A (zh) * 2018-10-02 2021-07-23 波士顿科学国际有限公司 用于流体化和输送粉状剂的装置
US12226568B2 (en) 2020-06-05 2025-02-18 Cook Medical Technologies Llc Medical scopes for delivering therapeutic agents
US12318573B2 (en) 2013-10-02 2025-06-03 Cook Medical Technologies Llc Therapeutic agents for delivery using a catheter and pressure source

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863503A1 (fr) * 2003-12-12 2005-06-17 Genzyme Sas Dispositif de pulverisation d'une poudre
US20050205087A1 (en) * 2004-03-17 2005-09-22 Genzyme Corporation Powder delivery device
US20100305505A1 (en) * 2009-05-29 2010-12-02 Ducharme Richard W Systems and methods for delivering therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863503A1 (fr) * 2003-12-12 2005-06-17 Genzyme Sas Dispositif de pulverisation d'une poudre
US20050205087A1 (en) * 2004-03-17 2005-09-22 Genzyme Corporation Powder delivery device
US20100305505A1 (en) * 2009-05-29 2010-12-02 Ducharme Richard W Systems and methods for delivering therapeutic agents

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12318573B2 (en) 2013-10-02 2025-06-03 Cook Medical Technologies Llc Therapeutic agents for delivery using a catheter and pressure source
CN113164723A (zh) * 2018-10-02 2021-07-23 波士顿科学国际有限公司 用于流体化和输送粉状剂的装置
CN113164723B (zh) * 2018-10-02 2023-12-19 波士顿科学国际有限公司 用于流体化和输送粉状剂的装置
US12226568B2 (en) 2020-06-05 2025-02-18 Cook Medical Technologies Llc Medical scopes for delivering therapeutic agents

Also Published As

Publication number Publication date
EP2934629A1 (fr) 2015-10-28

Similar Documents

Publication Publication Date Title
US12318573B2 (en) Therapeutic agents for delivery using a catheter and pressure source
US9375533B2 (en) Systems and methods for delivering therapeutic agents
AU2010253997B2 (en) Systems and methods for delivering therapeutic agents
CA2723183C (fr) Appareil et procedes pour administrer des agents therapeutiques
WO2014099662A1 (fr) Systèmes et procédés d'administration d'agents thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13818576

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013818576

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE